Find key information on Irritable Bowel Syndrome with Constipation IBS-C including diagnostic criteria ICD-10 K5902 Rome IV criteria clinical documentation tips medical coding guidelines and healthcare resources. Learn about symptom management treatment options and best practices for accurate IBS-C diagnosis coding and documentation. This resource provides valuable information for healthcare professionals medical coders and billers seeking clarity on Irritable Bowel Syndrome Constipation.
Also known as
Diseases of the digestive system
Covers various digestive disorders including IBS.
Noninfective gastroenteritis and colitis
Includes functional bowel disorders like IBS.
Functional intestinal disorders
Specifically designates functional bowel problems.
Follow this step-by-step guide to choose the correct ICD-10 code.
Meets Rome IV criteria for IBS?
When to use each related code
| Description |
|---|
| IBS with constipation (IBS-C) |
| Functional constipation |
| Chronic idiopathic constipation |
Coding IBS-C without specifying constipation (K58.0) when documentation supports it leads to undercoding and lost revenue.
Miscoding overlapping symptoms like abdominal pain (R10.x) separately from IBS-C (K58.0) can trigger audits for unbundling.
Diagnosing IBS-C without sufficient clinical evidence in patient records poses significant compliance risks and potential denials.
Q: How to differentiate Irritable Bowel Syndrome with Constipation (IBS-C) from other constipation-predominant functional gastrointestinal disorders in clinical practice?
A: Differentiating IBS-C from other functional constipation disorders like functional constipation or dyssynergic defecation requires a comprehensive assessment. While all involve chronic constipation, IBS-C is characterized by abdominal pain related to bowel movements, altered stool form (Bristol Stool Chart Type 1-2), and a change in stool frequency. Functional constipation focuses primarily on infrequent or difficult bowel movements without the mandatory pain association. Dyssynergic defecation involves impaired coordination of pelvic floor muscles during defecation. A thorough history, physical exam, and potentially anorectal manometry or defecography can aid in distinguishing these conditions. Consider implementing validated diagnostic criteria like the Rome IV criteria for IBS-C to ensure accurate diagnosis and guide treatment. Explore how integrating patient-reported outcome measures can enhance diagnostic accuracy and monitor treatment response.
Q: What are the most effective evidence-based pharmacologic and non-pharmacologic management strategies for patients with IBS-C refractory to first-line therapies like fiber and osmotic laxatives?
A: For IBS-C patients unresponsive to initial therapies, clinicians should consider second-line options. Pharmacologically, secretagogues like lubiprostone or linaclotide can stimulate intestinal fluid secretion, while the 5-HT4 agonist prucalopride can enhance colonic motility. Guanylate cyclase-C agonists like plecanatide represent another option. Non-pharmacologically, biofeedback therapy, specifically pelvic floor retraining, can address dyssynergic defecation contributing to IBS-C. Cognitive Behavioral Therapy (CBT) can also help manage the psychological distress often associated with IBS-C and improve coping mechanisms. Learn more about emerging therapies like fecal microbiota transplantation and how they might play a role in managing refractory IBS-C. Always consider patient preferences and comorbidities when tailoring a treatment plan.
Patient presents with chronic symptoms consistent with Irritable Bowel Syndrome with Constipation (IBS-C). The patient reports experiencing infrequent bowel movements, typically less than three per week, along with significant straining, hard or lumpy stools, and a sensation of incomplete evacuation. Abdominal pain and discomfort, including bloating and distension, are also reported. Symptom onset was approximately [duration] ago. The patient denies any unintentional weight loss, rectal bleeding, fever, or family history of colon cancer. Physical examination reveals normal bowel sounds and mild tenderness upon palpation of the lower abdomen. No masses were palpable. Rectal examination was unremarkable. Symptoms meet the Rome IV criteria for IBS-C. Differential diagnoses considered include chronic constipation, dyssynergic defecation, and other functional gastrointestinal disorders. Laboratory tests, including complete blood count (CBC) and comprehensive metabolic panel (CMP), were within normal limits. A fecal calprotectin test was ordered to rule out inflammatory bowel disease (IBD). The patient's current medication list includes [list medications]. The initial treatment plan includes increasing dietary fiber intake, ensuring adequate hydration, and initiating a trial of osmotic laxatives such as polyethylene glycol (PEG). Patient education regarding lifestyle modifications, including regular exercise and stress management techniques, was provided. Follow-up appointment scheduled in [duration] to assess treatment response and adjust management as needed. ICD-10 code K59.04 (Irritable bowel syndrome with constipation) is assigned.